Co-Diagnostics Stock Jumps After Completion of Bundibugyo Assay Strategy
Co-Diagnostics Inc. shares rose sharply in morning trading after the company said it completed its assay development strategy for the Bundibugyo virus, the Ebola strain behind outbreaks in the Democratic Republic of the Congo and Uganda. The firm said its Co-Dx PCR point-of-care platform would be used for the assay, which remains under regulatory r…